Publication number: 20240239774
Abstract: Provided herein are soluble adenylyl cyclase (sAC) inhibitors and uses thereof. In one aspect, provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and pharmaceutical compositions thereof. The compounds provided herein are soluble adenylyl cyclase (sAC) inhibitors and are therefore useful for the treatment and/or prevention of various diseases and conditions (e.g., ocular conditions (e.g., ocular hypotony), liver diseases (e.g., non-alcoholic steatohepatitis (NASH)), inflammatory diseases, autoimmune diseases (e.g., psoriasis)). Compounds provided herein are also useful as contraceptive agents (e.g., for male and female contraception).
Type:
Application
Filed:
April 27, 2022
Publication date:
July 18, 2024
Applicants:
Cornell University, Tri-Institutional Therapeutics Discovery Institue, Inc.
Inventors:
Melanie Balbach, Jochen Buck, Lonny R. Levin, Jonathan Hale Zippin, Clemens Steegborn, Makoto Fushimi, David John Huggins, Nigel Liverton, Peter T. Meinke, Mayako Michino, Michael Miller